What is the recommended dose of tetanus immunoglobulin (TIG) for the treatment of active tetanus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tetanus Immunoglobulin Dosage for Active Tetanus Treatment

For the treatment of active tetanus, the recommended dose of tetanus immunoglobulin (TIG) is 3,000-6,000 units administered intramuscularly. 1

Dosing Guidelines for Active Tetanus

  • The standard therapeutic dose for active tetanus cases should be adjusted according to the severity of infection, with 3,000-6,000 units being the typical range 1
  • This is significantly higher than the 250 units used for prophylaxis in wound management 2
  • TIG should be administered intramuscularly, distributing the total dose across multiple injection sites to enhance absorption 1
  • When administering TIG, it must be given at a different site than any tetanus toxoid-containing vaccine using separate syringes 2, 1

Treatment Protocol for Active Tetanus

  • Immediate administration of TIG is essential as part of standard therapy for active tetanus 1
  • Proper wound care remains paramount importance in conjunction with TIG administration 1
  • Note that in approximately 10% of recent tetanus cases, no wound or breach in skin or mucous membrane could be identified 1
  • TIG works by neutralizing circulating tetanus toxin but cannot neutralize toxin already bound to nerve endings 3

Alternative Administration Routes

  • Some research suggests potential benefits of intrathecal TIG administration in active tetanus cases:
    • A randomized controlled trial showed better clinical progression with combined intrathecal (250 units) plus intramuscular TIG compared to intramuscular route alone 4
    • Meta-analysis of 12 trials (942 patients) demonstrated reduced mortality with intrathecal administration (RR 0.71,95% CI 0.62-0.81) 5
    • However, intrathecal administration is not included in current CDC guidelines or FDA labeling 3, 1

Special Considerations

  • Inspect TIG visually for particulate matter and discoloration prior to administration 1
  • Do not use if particulate matter and/or discoloration are present 1
  • Follow proper sharps disposal procedures after administration 1
  • A number of factors could reduce efficacy, including improper storage and handling, so follow directions carefully 1

Clinical Pearls

  • Active tetanus is a medical emergency requiring immediate treatment
  • TIG should be administered as soon as possible after diagnosis
  • The higher therapeutic dose (3,000-6,000 units) reflects the need to neutralize circulating toxin in active disease versus the prophylactic dose (250 units) for wound management 1
  • Despite proper treatment, tetanus still carries significant mortality risk, emphasizing the importance of prevention through proper immunization 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.